Drug Interactions
Comprehensive guide to drug-drug interactions, pharmacokinetic interactions, and interaction management.
Browse the pages below for detailed information.
benzquinamide — COX-2 Interaction
Drug-target interaction between benzquinamide and COX-2. Synthetic organic pharmacological agent targeting this protein.
benzquinamide — D2 receptor Interaction
Drug-target interaction between benzquinamide and D2 receptor. Synthetic organic pharmacological agent targeting this protein.
betamethasone — Glucocorticoid receptor Interaction
Drug-target interaction between betamethasone and Glucocorticoid receptor. Metabolite pharmacological agent targeting this protein.
betaxolol — β1-adrenoceptor Interaction
Drug-target interaction between betaxolol and β1-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
bethanechol — M2 receptor Interaction
Drug-target interaction between bethanechol and M2 receptor. Synthetic organic pharmacological agent targeting this protein.
bethanechol — M3 receptor Interaction
Drug-target interaction between bethanechol and M3 receptor. Synthetic organic pharmacological agent targeting this protein.
betrixaban — coagulation factor X Interaction
Drug-target interaction between betrixaban and coagulation factor X. Synthetic organic pharmacological agent targeting this protein.
bexagliflozin — Sodium/glucose cotransporter 2 Interaction
Drug-target interaction between bexagliflozin and Sodium/glucose cotransporter 2. Synthetic organic pharmacological agent targeting this protein.
bexarotene — Retinoid X receptor-α Interaction
Drug-target interaction between bexarotene and Retinoid X receptor-α. Synthetic organic pharmacological agent targeting this protein.
bexarotene — Retinoid X receptor-β Interaction
Drug-target interaction between bexarotene and Retinoid X receptor-β. Synthetic organic pharmacological agent targeting this protein.
bexarotene — Retinoid X receptor-γ Interaction
Drug-target interaction between bexarotene and Retinoid X receptor-γ. Synthetic organic pharmacological agent targeting this protein.
bezafibrate — Peroxisome proliferator-activated receptor-α Interaction
Drug-target interaction between bezafibrate and Peroxisome proliferator-activated receptor-α. Synthetic organic pharmacological agent targeting this protein.
bicalutamide — Androgen receptor Interaction
Drug-target interaction between bicalutamide and Androgen receptor. Synthetic organic pharmacological agent targeting this protein.
bimatoprost — FP receptor Interaction
Drug-target interaction between bimatoprost and FP receptor. Synthetic organic pharmacological agent targeting this protein.
binimetinib — mitogen-activated protein kinase kinase 1 Interaction
Drug-target interaction between binimetinib and mitogen-activated protein kinase kinase 1. Synthetic organic pharmacological agent targeting this protein.
binimetinib — mitogen-activated protein kinase kinase 2 Interaction
Drug-target interaction between binimetinib and mitogen-activated protein kinase kinase 2. Synthetic organic pharmacological agent targeting this protein.
biperiden — M1 receptor Interaction
Drug-target interaction between biperiden and M1 receptor. Synthetic organic pharmacological agent targeting this protein.
bireociclib — cyclin dependent kinase 4 Interaction
Drug-target interaction between bireociclib and cyclin dependent kinase 4. Synthetic organic pharmacological agent targeting this protein.
bireociclib — cyclin dependent kinase 6 Interaction
Drug-target interaction between bireociclib and cyclin dependent kinase 6. Synthetic organic pharmacological agent targeting this protein.
bivalirudin — coagulation factor II, thrombin Interaction
Drug-target interaction between bivalirudin and coagulation factor II, thrombin. Peptide pharmacological agent targeting this protein.
blonanserin — 5-HT2A receptor Interaction
Drug-target interaction between blonanserin and 5-HT2A receptor. Synthetic organic pharmacological agent targeting this protein.
blonanserin — D2 receptor Interaction
Drug-target interaction between blonanserin and D2 receptor. Synthetic organic pharmacological agent targeting this protein.
bortezomib — proteasome 20S subunit beta 5 Interaction
Drug-target interaction between bortezomib and proteasome 20S subunit beta 5. Synthetic organic pharmacological agent targeting this protein.
bosentan — ETB receptor Interaction
Drug-target interaction between bosentan and ETB receptor. Synthetic organic pharmacological agent targeting this protein.
bosutinib — ABL proto-oncogene 1, non-receptor tyrosine kinase Interaction
Drug-target interaction between bosutinib and ABL proto-oncogene 1, non-receptor tyrosine kinase. Synthetic organic pharmacological agent targeting this protein.
brensocatib — cathepsin C Interaction
Drug-target interaction between brensocatib and cathepsin C. Synthetic organic pharmacological agent targeting this protein.
brentuximab vedotin — CD30 Interaction
Drug-target interaction between brentuximab vedotin and CD30. Antibody pharmacological agent targeting this protein.
brigatinib — ALK receptor tyrosine kinase Interaction
Drug-target interaction between brigatinib and ALK receptor tyrosine kinase. Synthetic organic pharmacological agent targeting this protein.
brimonidine (UK14304) — α2A-adrenoceptor Interaction
Drug-target interaction between brimonidine (UK14304) and α2A-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
brimonidine (UK14304) — α2B-adrenoceptor Interaction
Drug-target interaction between brimonidine (UK14304) and α2B-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
brimonidine (UK14304) — α2C-adrenoceptor Interaction
Drug-target interaction between brimonidine (UK14304) and α2C-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
brinzolamide — carbonic anhydrase 7 Interaction
Drug-target interaction between brinzolamide and carbonic anhydrase 7. Synthetic organic pharmacological agent targeting this protein.
brivaracetam — synaptic vesicle glycoprotein 2A Interaction
Drug-target interaction between brivaracetam and synaptic vesicle glycoprotein 2A. Synthetic organic pharmacological agent targeting this protein.
brodalumab — Interleukin 17 receptor A Interaction
Drug-target interaction between brodalumab and Interleukin 17 receptor A. Antibody pharmacological agent targeting this protein.
bromfenac — COX-1 Interaction
Drug-target interaction between bromfenac and COX-1. Synthetic organic pharmacological agent targeting this protein.
bromocriptine — D2 receptor Interaction
Drug-target interaction between bromocriptine and D2 receptor. Synthetic organic pharmacological agent targeting this protein.
bromocriptine — D3 receptor Interaction
Drug-target interaction between bromocriptine and D3 receptor. Synthetic organic pharmacological agent targeting this protein.
bromocriptine — D4 receptor Interaction
Drug-target interaction between bromocriptine and D4 receptor. Synthetic organic pharmacological agent targeting this protein.
budesonide — Glucocorticoid receptor Interaction
Drug-target interaction between budesonide and Glucocorticoid receptor. Synthetic organic pharmacological agent targeting this protein.
bumetanide — Kidney-specific Na-K-Cl symporter Interaction
Drug-target interaction between bumetanide and Kidney-specific Na-K-Cl symporter. Synthetic organic pharmacological agent targeting this protein.
bunolol — β1-adrenoceptor Interaction
Drug-target interaction between bunolol and β1-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
bunolol — β2-adrenoceptor Interaction
Drug-target interaction between bunolol and β2-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
bunolol — β3-adrenoceptor Interaction
Drug-target interaction between bunolol and β3-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
bupranolol — β1-adrenoceptor Interaction
Drug-target interaction between bupranolol and β1-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
bupranolol — β2-adrenoceptor Interaction
Drug-target interaction between bupranolol and β2-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
bupranolol — β3-adrenoceptor Interaction
Drug-target interaction between bupranolol and β3-adrenoceptor. Synthetic organic pharmacological agent targeting this protein.
buprenorphine — κ receptor Interaction
Drug-target interaction between buprenorphine and κ receptor. Synthetic organic pharmacological agent targeting this protein.
buprenorphine — μ receptor Interaction
Drug-target interaction between buprenorphine and μ receptor. Synthetic organic pharmacological agent targeting this protein.
bupropion — DAT Interaction
Drug-target interaction between bupropion and DAT. Synthetic organic pharmacological agent targeting this protein.
bupropion — NET Interaction
Drug-target interaction between bupropion and NET. Synthetic organic pharmacological agent targeting this protein.
buspirone — 5-HT1A receptor Interaction
Drug-target interaction between buspirone and 5-HT1A receptor. Synthetic organic pharmacological agent targeting this protein.
butorphanol — κ receptor Interaction
Drug-target interaction between butorphanol and κ receptor. Synthetic organic pharmacological agent targeting this protein.
butorphanol — μ receptor Interaction
Drug-target interaction between butorphanol and μ receptor. Synthetic organic pharmacological agent targeting this protein.
cabazitaxel — tubulin beta class I Interaction
Drug-target interaction between cabazitaxel and tubulin beta class I. Synthetic organic pharmacological agent targeting this protein.
cabergoline — D2 receptor Interaction
Drug-target interaction between cabergoline and D2 receptor. Synthetic organic pharmacological agent targeting this protein.
cabozantinib — kinase insert domain receptor Interaction
Drug-target interaction between cabozantinib and kinase insert domain receptor. Synthetic organic pharmacological agent targeting this protein.
cabozantinib — MET proto-oncogene, receptor tyrosine kinase Interaction
Drug-target interaction between cabozantinib and MET proto-oncogene, receptor tyrosine kinase. Synthetic organic pharmacological agent targeting this protein.
cadonilimab — cytotoxic T-lymphocyte-associated protein 4 (CD152) Interaction
Drug-target interaction between cadonilimab and cytotoxic T-lymphocyte-associated protein 4 (CD152). Antibody pharmacological agent targeting this protein.
cadonilimab — programmed cell death 1 (CD279) Interaction
Drug-target interaction between cadonilimab and programmed cell death 1 (CD279). Antibody pharmacological agent targeting this protein.
caffeine — A1 receptor Interaction
Drug-target interaction between caffeine and A1 receptor. Natural product pharmacological agent targeting this protein.